Everest Medicines Empowers Biopharmaceutical Revolution with Appointment of New Chief Technology Officer

With his extensive experience and expertise, Dr. Berry’s appointment signifies Everest’s commitment to revolutionize drug development and manufacturing, bringing innovative therapies to patients in Greater China and beyond.

In a groundbreaking development, Everest Medicines, the renowned biopharmaceutical company specializing in innovative medicines and vaccines, has announced the immediate appointment of Dr. Mike Berry as their new Chief Technology Officer. Dr. Berry’s vast experience spans over three decades, during which he has successfully propelled numerous projects from pre-clinical development to commercialization.

Dr. Berry’s exceptional expertise lies in the development, scale-up, and manufacturing of biopharmaceuticals, accompanied by an in-depth understanding of international regulatory guidelines such as Good Manufacturing Practices (GMP) and Chemistry, Manufacturing and Control (CMC). As the newly appointed Chief Technology Officer, Dr. Berry will assume responsibility for Everest’s comprehensive CMC activities, overseeing operations and management of their cutting-edge manufacturing facility located in Jiashan, Zhejiang. This state-of-the-art facility, conforming to both global and Chinese GMP standards, boasts an impressive annual production capacity of 700 million doses of mRNA vaccines.

Rogers Yongqing Luo, the Chief Executive Officer of Everest Medicines, expressed his enthusiasm for Dr. Berry’s arrival, stating, “Dr. Berry brings invaluable expertise and extensive experience in CMC and manufacturing that will further strengthen our complete industrial value chain. His contributions will enhance our self-discovery and manufacturing capabilities, facilitating our transition from a clinical-stage biotech firm to a fully-integrated biopharmaceutical powerhouse.”

Dr. Berry, equally delighted by the opportunity, shared his vision for Everest Medicines, saying, “I am thrilled to join Everest and contribute to delivering vital therapies that address critical unmet medical needs in Greater China and other Asian countries. Leveraging my expertise, I aim to develop and produce innovative drugs and vaccines at Everest, utilizing scalable, efficient, and consistent manufacturing processes.”

Prior to this significant appointment, Dr. Berry served as the Chief Technical Operations Officer for global operations at Clover Biopharmaceuticals, Ltd., overseeing the development and manufacturing of Clover’s drug substance and drug products worldwide. His distinguished career also includes leadership roles at various renowned biotech companies, including Dynavax Technologies Corp., Novartis Diagnostics, and a notable tenure as a CMC consultant at BioTechLogic, Inc. His extensive experience encompasses the development, manufacturing, and testing of both large and small molecule drug substances and drug products, as well as drug product supply chain management.

Dr. Berry, a distinguished alumnus of the University of Manitoba, Canada, holds a Ph.D. in microbiology.

This appointment marks a significant milestone for Everest Medicines as they solidify their position as a prominent player in the biopharmaceutical industry. Dr. Berry’s arrival is poised to drive the company’s transformative journey towards becoming a fully-integrated biopharmaceutical powerhouse, capable of delivering innovative therapies to patients across the Greater China region and beyond.